Table 3.
Characterization of Complications1
| CMRI screened participants with current EDIC data (N=1240) | Participants with CMRI (N=1017) | Participants with CMRI & IMT (N=889) | |
|---|---|---|---|
| Cardiovascular Disease | N (%) | N (%) | N (%) |
| Clinical or Silent MI | 52 (4.2) | 37 (3.6) | 30 (3.4) |
| Adjudicated Clinical MI Events | 24 (1.9) | 14 (1.4) | 10 (1.1) |
| Silent MI | 30 (2.4) | 23 (2.3) | 20 (2.3) |
| CAC score > 0 (%) (year 7–9) | 343 (30.6) | 282 (30.3) | 244 (29.4) |
| CAC score > 200 (%) (year 7–9) | 88 (7.9) | 67 (7.2) | 56 (6.8) |
| Retinopathy | |||
| PDR or worse | 252 (20.3) | 206 (20.3) | 181 (20.4) |
| Nephropathy | |||
| Macroalbuminuria/ESRD2 | 124 (10.0) | 98 (9.6) | 81 (9.1) |
| Sustained Microalbuminuria/ESRD3 | 338 (27.3) | 269 (26.5) | 232 (26.1) |
| Neuropathy4 | |||
| Autonomic Neuropathy | 377 (32.2) | 310 (31.7) | 270 (31.3) |
| Peripheral Neuropathy | 342 (30.0) | 282 (29.4) | 245 (28.9) |
| All Complications5 | |||
| Participants with 0 complication | 694 (56.0) | 578 (56.8) | 507 (57.0) |
| Participants with 1 complication | 351 (28.3) | 277 (27.2) | 241 (27.1) |
| Participants with 2 complications | 138 (11.1) | 116 (11.4) | 104 (11.7) |
| Participants with ≥ 3 complications | 57 (4.6) | 46 (4.5) | 37 (4.2) |
1
All complications were cumulative from DCCT to EDIC year 14–16 except for neuropathy.
2
AER ≥ 300 mg/24hr or ESRD
3
AER ≥ 30 mg/24hr consecutive two visits or ESRD
4
Neuropathy data was obtained once at EDIC year 13/14.
5
All complications were defined having clinical or silent MI, PDR or worse, macroalbuminuria/ESRD, or autonomic neuropathy